-
Ultrasound is a use you may not have thought of: to open the blood-brain barrier and send in anti-cancer drugs
Time of Update: 2022-09-14
He then enrolled in a clinical trial at the University of Maryland Medical Center to test a new treatment: to break through the blood-brain barrier and facilitate the entry of chemotherapy drugs into brain lesions.
-
Clin Cancer Res: Navumab plus docetaxel significantly prolongs survival in patients treated with ICI and NSCLC
Time of Update: 2022-09-14
Researchers such as Yuri Taniguchi conducted an open-label randomized Phase II/III study to evaluate the efficacy of navumab plus docetaxel combination therapy compared to navumab monotherapy in previously treated ICI-treated non-small cell lung cancer (NSCLC).
-
Cheng Liang's team from Soochow University and Professor Dong Zhiqiang of Huazhong Agricultural University AS: Titanium sulfide nanosheets are used as cascaded bioreactors for gas-sonic dynamic combination therapy of cancer
Time of Update: 2022-09-14
Keywords: titanium sulfide nanosheets, nano cascade reactors, hydrogen sulfide, gas therapy, acoustic dynamic therapyAcoustic dynamic therapy (SDT) is a new type of medical treatment, mainly in the presence of voice sensitizers, through local ultrasound to produce a large number of reactive oxygen species (ROS) to play a good killing effect, because of its high tissue penetration depth, good aggregation specificity and negligible side effects and other characteristics have been widely concerned.
-
Skin Res Technol: High-frequency ultrasound to differentiate between high-risk basal cell carcinoma and cutaneous squamous cell carcinoma
Time of Update: 2022-09-14
Many non-invasive and immediate techniques, such as dermoscopy, optical coherence tomography (OCT), reflective confocal microscopy (RCM), and high-frequency ultrasound (HFUS), are increasingly being used to diagnose skin cancer.
-
Medical interview with Professor Xie Ke: Attach importance to the standardized management of whitening and break the shackles of chemotherapy safety
Time of Update: 2022-09-14
Therefore, the Physician's Daily specially invited Professor Xie Ke of Sichuan Provincial People's Hospital to share the clinical treatment experience of patients with bone marrow suppression after chemotherapy, and to explore the best management plan for patients with bone marrow suppression after chemotherapy under comprehensive evaluation and effective prevention.
-
Research status and future direction of tumor bacterial immunotherapy
Time of Update: 2022-09-14
In addition, the strain polarized macrophages to the anti-tumor M1 phenotype, enriched the Th1 cell population with a large amount of TNF-α, and reduced the expression of IL-10, thus showing enhanced therapeutic effects in combination chemotherapy-immunotherapy.
-
Express Disease control rate 100%! The combination of KRAS inhibitors in the treatment of colorectal cancer yielded positive results
Time of Update: 2022-09-14
▲If you have any business needs, please long press to scan the QR code above, or▎ WuXi AppTec content team editorMirati Therapeutics today announced the results of a latest clinical trial of KRAS G12C inhibitor adagrasib as a single agent, or in combination with the EGFR inhibitor cetuximab, for the treatment of patients with advanced treated colorectal cancer with mutations in the KRAS G12C gene.
-
Nature Sub-Journal: This metabolic "waste" rejuvenates anti-tumor immune cells
Time of Update: 2022-09-14
In a new study published in Nature Communications on September 7, Beijing time, a research team from the University of Texas Southwestern Medical Center first elucidated that lactic acid promotes anti-tumor immunity by increasing CD8+ T cells in a variety of tumor models.
-
Express significantly prolongs the overall survival of patients with metastatic breast cancer! Results of the latest Phase 3 trial of Gilead ADCs are announced
Time of Update: 2022-09-14
Data analysis published in March showed that patients in the Trodelvy treatment group achieved statistically significant improvements in the trial's primary endpoint progression-free survival (PFS).
Data analysis published in March showed that patients in the Trodelvy treatment group achieved statistically significant improvements in the trial's primary endpoint progression-free survival (PFS).
-
Express ORR up to 59.8%! Di zhe pharmaceutical suvotinib lung cancer registration study reached the main endpoint
Time of Update: 2022-09-14
▲If you have any business needs, please long press to scan the QR code above, or▎ WuXi AppTec content team reportsRecently, Di zhe Pharmaceutical announced that the first registered study of suvotinib in patients with advanced non-small cell lung cancer (NSCLC) who had previously received platinum chemotherapy and carried EGFR exon20ins had reached the main endpoint.
-
The development of tumor immunity from the therapeutic field
Time of Update: 2022-09-14
One of the mechanisms to overcome the limitations of PD-1 treatment is to target other immune checkpoints associated with the tumor microenvironment, such as LAG-3, TIGIT, TIM-3, VISTA, B7-H3, ICOS, and BTLA, which are feasible and promising options for treating solid tumors, and are currently being actively studied in multiple clinical trials.
-
Research progress and targeting strategies of tumor-associated extracellular matrix
Time of Update: 2022-09-14
Other substances in ECM, such as FN, hyaluronic acid (HA), laminins, and matrix metalloproteinases (MMPs), interact with collagen through integrins, disc domain receptors (DDRs), tyrosine kinase receptors, and some signaling pathways, thereby influencing the behavior and activity of cancer cells.
-
J Clin Oncol: Immunogenicity and efficacy of generic cancer vaccines in advanced non-small cell lung cancer
Time of Update: 2022-09-14
The Phase IB/IIa clinical trial was designed to evaluate the safety, immunogenicity and efficacy of the UCPVax three-dose regimen in patients with metastatic non-small cell lung cancer (NSCLC).
-
The application of T cell sorting in car-T cell preparation and its future development trend are discussed
Time of Update: 2022-09-14
： ， 。 Video Applet Like, double tap to cancel Like in Watch, tap twice to cancel Watch Importance in cell therapy for bead sortingSince Emily Whitehead brought new hope for cancer cures, CAR-T cell therapy has once again cemented its central position in the field of immune cell therapy.
-
Survival prognosis for glial sarcoma is associated with MGMT promoter methylation and temozolomide
Time of Update: 2022-09-14
The current treatment model for gliosarcoma is to refer to the maximum safety resection of traditional glioblastoma, adjuvant radiotherapy and temozolomide chemotherapy; The patient's median overall survival was only 13 months.
-
Note! Children's chemotherapy drugs are careful of "ototoxicity"
Time of Update: 2022-09-14
Download the Doctor Station App and subscribe anytime, anywhere*For medical professionals onlyLearn a hot medicine every day As one of the most commonly used drugs in current combination chemotherapy, cisplatin is effective against a variety of solid tumors, but its incidence of nephrotoxicity is high, so it requires a lot of hydration during and after chemotherapy.
-
BMC Ophthalmol: 5-year observation of basal cell carcinoma around the eye
Time of Update: 2022-09-14
BMC Ophthalmol 2022 Jun 28; 22(1) Basal cell carcinoma (BCC) is a non-melanoma skin cancer type and the most common type of skin cancer in Denmark.
BMC Ophthalmol 2022 Jun 28; 22(1) Basal cell carcinoma (BCC) is a non-melanoma skin cancer type and the most common type of skin cancer in Denmark.
-
【Philips daily case】【Misdiagnosis analysis】Hepatic angiomyolipoma is misdiagnosed as a case of liver cancer
Time of Update: 2022-09-14
Comments:At present, common clinical examination methods for diagnosing liver cancer include the detection of alpha-fetoprotein in the blood, fucoidase, imaging tests, etc.
Comments:At present, common clinical examination methods for diagnosing liver cancer include the detection of alpha-fetoprotein in the blood, fucoidase, imaging tests, etc.
-
With a 5-year survival rate of 84%, the "weapon" of the United States to treat endometrial cancer is precision surgery and rational medication!
Time of Update: 2022-09-14
In January, the New England Journal of Medicine published findings showing that the combination of Keytruda+Lenvima significantly prolonged the survival of patients with advanced endometrial cancer compared with the chemotherapy group 。 Specifically, the median overall survival in the Keytruda+Lenvima group was 18.
-
Consultation analysis (2022.8.30): Considering the nature of the tumor, multiple nodules in both lungs are also showing back pain, is it a danger signal?
Time of Update: 2022-09-14
Basic information:Female 58 years oldDisease Description:Back pain, chest CT after the discovery of ground glass nodules, please give judgment to the director. Image display and analysis:Let's first l
